Theseus Pharmaceuticals, Inc. (THRX)

-- Theseus Stockholders to Receive $4.05 Per Share in Cash Plus Contingent Value Right -- CAMBRIDGE, Mass. , Feb. 14, 2024 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus" or the "Company"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies, today announced that Concentra Biosciences, LLC ("Concentra") through its wholly owned subsidiary, Concentra Merger Sub II, Inc. ("Merger Sub"), has successfully completed the previously announced tender offer to acquire all outstanding shares of Theseus common stock for a price per share of (i) $4.05 in cash (the "Cash Amount"), plus (ii) one non-tradeable contingent value right per share (each, a "CVR" and each CVR together with the Cash Amount, the "Offer Price") representing the right to receive 80% of the net proceeds from any license or disposition of certain of Theseus' programs effected within 180 days of the close of the merger and 50% of the potential aggregate value of certain specified potential cost savings realized within 180 days of the close of the merger, pursuant to a Contingent Value Rights Agreement.

NEW ORLEANS , Jan. 22, 2024 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Theseus Pharmaceuticals, Inc. (NasdaqGS: THRX) to Concentra Biosciences, LLC. Under the terms of the proposed transaction, shareholders of Theseus will receive between $3.90 and $4.05 in cash for each share of Theseus that they own. KSF is seeking to determine whether this consideration and the process that le.

Theseus Pharmaceuticals (THRX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

MILWAUKEE , Dec. 22, 2023 /PRNewswire/ -- Ademi LLP is investigating Theseus (NASDAQ: THRX) for possible breaches of fiduciary duty and other violations of law in its transaction with Concentra. Click here to learn how to join the https://www.ademilaw.com/case/theseus-pharmaceuticals-inc or call Guri Ademi toll-free at 866-264-3995.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) to Concentra Biosciences, LLC for between $3.90 and $4.05 in cash is fair to Theseus shareholders. Halper Sadeh encourages Theseus shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation con.

CAMBRIDGE, Mass. , Dec. 22, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus" or the "Company"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies, today announced it has entered into a definitive merger agreement (the "Merger Agreement") whereby Concentra Biosciences, LLC ("Concentra") will acquire Theseus for a price per share of Theseus common stock ("Theseus common stock") of between $3.90 and $4.05 in cash, consisting of (i) a base cash price of $3.90 per share (the "Base Price") and (ii) an additional cash amount of not more than $0.15 per share at the closing of the merger (together with the Base Price, the "Cash Amount"), plus one non-tradeable contingent value right ("CVR") representing the right to receive 80% of the net proceeds from any license or disposition of Theseus' programs effected within 180 days of closing of the merger and 50% of the potential aggregate value of certain specified potential cost savings realized within 180 days of the close of the merger, pursuant to a Contingent Value Rights Agreement (the "CVR Agreement").

Theseus (THRX) gains 57% in a month after announcing plans to conduct a process exploring strategic alternatives to maximize shareholder value. The company cuts its workforce by 72%.

CAMBRIDGE, Mass. , Nov. 27, 2023 /PRNewswire/ -- On November 22, 2023, the board of directors (the Board) of Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company) received an unsolicited joint letter from funds and persons affiliated with Foresite Capital, LLC (collectively, Foresite) and funds and persons affiliated with OrbiMed Advisors LLC (collectively, OrbiMed), in which Foresite and OrbiMed indicated their intent to explore and evaluate a potential acquisition of all of the outstanding shares of common stock of the Company not already owned by Foresite or OrbiMed in a going-private transaction.

Theseus Pharmaceuticals experienced significant losses after discontinuing its lead program, leaving it with a market cap of half of its current assets. THRX is now focusing on developing a fourth-generation EGFR inhibitor for the treatment of EGFR-mutated non-small cell lung cancer. The company has enough funds to sustain operations until 2026, but the success of its pipeline drugs remains uncertain.

The heavy selling pressure might have exhausted for Theseus Pharmaceuticals, Inc. (THRX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

IND submission for THE-349 in EGFR-mutant NSCLC expected in Q4 2023 Development candidate nomination for BCR-ABL program in CML and Ph+ ALL expected in H1 2024 Nomination of highly selective pan-variant KIT inhibitor candidate for GIST expected in H1 2024 Announces plans to explore the development of low dose THE-630 in mast cell-driven inflammatory indications based on dose-dependent reductions in serum tryptase levels in patients in GIST study $234.2 million of cash, cash equivalents, and marketable securities as of June 30, 2023 CAMBRIDGE, Mass. , Aug. 10, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies, today announced business highlights and reported financial results for the second quarter ended June 30, 2023.

SOHO, FUTU, NEOG, OPK and THRX have been added to the Zacks Rank #1 (Strong Buy) List on July 19, 2023.

The heavy selling pressure might have exhausted for Theseus Pharmaceuticals, Inc. (THRX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Theseus (THRX) announces the discontinuation of enrollment in its phase I/II study of THE-630 in patients with gastrointestinal stromal tumors due to observed adverse reactions. The stock falls 72%.